At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 230 enrolled
Drug / intervention
IRaydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Sham Controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
In Brief
A Phase 2 clinical trial evaluating IRay for AMD and 6 related conditions. Completed, enrolled 230 participants across 21 sites in 5 countries.
Detailed Summary
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Macular Degeneration, Eye Diseases, Retinal Diseases
CountriesAustria, Czechia, Germany, Italy, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionMay 2012
Study CompletionApr 2014
TodayJul 2026
First PostedNov 20, 2009
Enrollment StartNov 1, 2009
Primary CompletionMay 1, 2012
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 16.6 years ago
Interventions
IRaydevice
Low voltage stereotactic radiotherapy system